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Objective: This study aims to appraise 2017 AACE Guidelines for Management of Dyslipidemia 
and Prevention of Cardiovascular Disease by using Appraisal of Guidelines for Research and 
Evaluation II (AGREE II) tool. 
Method: A total of seven investigators who have obtained a postgraduate Doctor of Pharmacy 
or Masters of Clinical Pharmacy, appraised the dyslipidaemia guidelines independently, by using 
AGREE II tool. 
Key findings: Among all the domains, the highest-scoring domain was the clarity of presentation 
(87%), and the lowest was the applicability (26%). The assessors gave the top ranking for both 
‘scope and purpose’ (78%) and ‘Editorial independence’ (79%). The overall guideline assessment 
was 61%. Most of the investigators (four out of seven) recommended using the guidelines in 
clinical practice with modifications. 
Conclusion: The appraisal obtained in this article can be utilized by guideline developers to 
improve the quality of their upcoming guidelines. Healthcare professionals can be aware of 
guideline limitations and the importance of quality assessment of the guideline before applying 
their recommendations whenever possible by using Agree II tool. 
 
 







‘Clinical Practice Guidelines’, are defined by the Institute of Medicine as, ‘Statements  that include 
recommendations, intended to optimize patient care, that are informed by a systematic review 
of evidence and an assessment of the benefits and harms of alternative care options’.[1] 
Historically, the Clinical Guidelines were designed to improve the quality and safety of health 
care.[2] They have mainly focused on the size of effectiveness and the cost of interventions as 
well as the feasibility of applying the guidelines; however, recently ‘Patient-Specific factors’ are 
also incorporated to guide the treatment decisions, improve the quality and reduce the cost.[2] 
Many standard methodologies and development strategies have been established to enhance the 
quality of new or updated guidelines; however, the adherence of the practice guidelines to the 
standards and development strategies is poor.[3] Many key points  are often not considered in 
developing guidelines, For example, ‘Data Collection’, ‘Method Given’ and ‘Quality of Evidence 
Rated’. Moreover, the differences in opinions among guideline developers were not aired in 
guidelines and benefits of recommendations was given greater attention than potential 
harms.[4,5] 
As mentioned, the appraisals of guidelines are significantly important. We aimed to critically 
appraise the ‘Guidelines for management of Dyslipidemia and prevention of cardiology disease’. 
The 2017 AACE guideline which contains a total of 87 recommendations for a broader range of 
disease stages that include a new group of patients at risk and recommends more intense 






The appraisal of this guideline was done by using the Appraisal of Guidelines for Research and 
Evaluation II (AGREE II) instrument.[7] It is the only tool to assess the Table 1 Items and domains 
of the Appraisal of Guidelines for  Research and Evaluation II (AGREE II) instrument quality of 
any clinical practice guidelines in any diseased area that can be used by healthcare 
providers, guideline developers, policy makers and educators’. It was published in 2003 and 
refined in 2009. The AGREE II tool to be validated requires the appraisal of six domains that 
involve 23 ranking items with additional categories for ‘Overall Assessment’ and 
‘recommendations’ that scored with a 7-point scale. The domains include the following: 
scope and purpose, stakeholder involvement, rigour of development, clarity, and 
presentation, applicability and editorial independence. The largest number of key items is 
in the rigour of development section Table 1.[8] AGREE II tool manual is available to explain 
in detail the subsections of each domain.[6] The appraisers were asked to assign a grade 
between 1 (strongly disagree) and 7(strongly agree) for all the items, independently. At 
least two assessors (preferably four) are needed to appraise the guideline. Domain scores 
are calculated by summing up all the scores of the individual items in a domain and by 
scaling the total as a percentage of the maximum possible score for that domain Figure 1.[6] 
A total of seven investigators either a postgraduate Doctor of Pharmacy or Masters of Clinical 
Pharmacy appraised the dyslipidaemia guideline independently; then, they forwarded their 
individually scored tool to one investigator (R.M.A), who reviewed and made sure that no 
item had scores differently by six points or more between assessors. If this conflict happened, 






Among all domains, the highest-scoring domain was the clarity of presentation (87%), and the 
lowest was the applicability (26%). The assessors gave the top ranking for both ‘scope and 
purpose’ 78% and ‘Editorial independence’ 79%. The scoring for the others domain was as such: 
‘Stakeholder involvement’ 56%; ‘Rigour of development’ 35%; ‘Overall guideline assessment’ 
61%. Most of the investigators (four out of seven) recommended using the guideline in clinical 





The ‘clarity of presentation’ which is the highest ranked domain in our study is an essential 
aspect of using guidelines in practice; however, it does not indicate the methodological strength 
of guidelines. Moreover, it was reported as the highest ranking domain in many previous 
published reports.[9–11] 
The applicability should be weighted more heavily through identifying the types of facilitators, 
barriers and advice to the clinician according to their settings. Although the applicability score 
was the lowest, most of the assessors agreed to use the guidelines in practice due to the 
availability of tools, resources, monitoring and follow-up criteria that facilitate its application. 
For dyslipidaemia guidelines, the rigour of development which describes the methodology, 
consisting of seven items was scored (35%). This can be enhanced clearly by explaining the 
criteria for searching and selecting the evidence, providing a procedure for updating the 
guidelines and considering the health benefits, side effects and harms when formulating the 
recommendation. The low score for stakeholder involvement (56%) in dyslipidemia guideline 
was due to the lack of information about the intended user experience and views of healthcare 
professionals in the development process of the guidelines. More so, this information if included 







In conclusion, the appraisal obtained in this article can be utilized by guideline developers 
to improve the quality of their upcoming guidelines. Healthcare professionals can be aware 
of guideline limitations and the importance of quality assessment of the guideline before 








Table 1 – Items and domains of the Appraisal of Guidelines for Research and Evaluation II 
(AGREE II) instrument. 
 
Item Content Domain 
1 The overall objective(s) of the guideline is (are 
specifically described) 
Scope and purpose 
2 The health question(s) covered by the guideline is 
(are specifically described) 
3 The population (patients public etc.) to whom the 
guideline is meant to apply is specifically described 
4 The guideline development group includes individuals 
from all relevant professional groups 
Stakeholder involvement 
5 The views and preferences of the target population 
(patients public etc.) have been sought 
6 The target users of the guideline are clearly defined 
7 Systematic methods were used to search for evidence Rigour of development 
8 The criteria for selecting the evidence are clearly 
described 
9 The strengths and limitations of the body of evidence 
are clearly described 
10 The methods for formatting the recommendations 
are clearly described 
11 The health benefits, side effects and risks have been 
considered in formulating the recommendations 
12 There is an explicit link between the 
recommendations and the supporting evidence 
13 The guideline has been extremely reviewed by 
experts prior to its publication 
14 A procedure for updating the guideline is provided 
15 The recommendations are specific and 
unambiguous 
Clarity of presentation 
16 The different options for management of the 
condition or health issue are clearly presented 
17 Key recommendations are easily identifiable 
18 The guideline describes facilitators barriers to its 
application 
Applicability 
19 The guideline provides advice and/or tools on how the 
recommendations can be put into practice 
20 The potential resource implications of applying the 
recommendations have been considered 
21 The guideline presents monitoring and/or auditing 
criteria 
22 The views of the funding body have not influenced 
the content of the guideline 
Editorial independence 
23 Competing interest of guideline development group 
members have been recorded and addressed 
Extracted from the AGREE II instrument. 
 
A quality score is calculated for each of the six AGREE II domains. The six domain scores are 
independent and should not be aggregated into a single quality score. 
Calculating Domain Scores 
Domain scores are calculated by summing up all the scores of the individual items in a domain 




If 4 appraisers give the following scores for Domain 1 (Scope & Purpose): 
 







Appraiser 1 5 6 6 17 
Appraiser 2 6 6 7 19 
































Table 2 Summary of appraisal results  
Domain Scaled domain score (%)† 
Scope and purpose 78 
Stakeholder involvement 56 
Rigour of development 35 
Clarity of presentation 87 
Applicability 26 
Editorial independence 79 
Overall guideline assessment 61 
Overall guideline recommendation Yes, with modification 
†Based on scoring (on a 7-point Likert scale) by seven assessors, with standardized domain 
scores subsequently calculated according to AGREE II formula and reported as percentages 
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